Skip to main content
. 2022 Jun 7;12:911567. doi: 10.3389/fonc.2022.911567

Figure 4.

Figure 4

Analysis of survival and cumulative risk of relapse and early death for final low-risk patients with ETV6-RUNX1-positive ALL.